



## Sunday, September 23, 2018

07:00 - 09:30    **Type: Networking Opportunity**  
**Title: IASLC Foundation Walk**

07:00 - 12:00    **Type: Workshop**  
**Title: IASLC CT Screening Symposium: Forefront Advances in Lung Cancer Screening (Ticketed Session)**

Track: Screening and Early Detection  
Moderation: John Field, UK; James Mulshine, USA

07:00 - 07:30    **Breakfast**

07:30 - 07:35    **Introductions & Welcome**

**Session I: The Backbone to our Knowledge on Lung Cancer Screening**

07:35 - 07:50    **Lung Cancer Screening: 1999 to Date - What Have We Learnt?**

David Yankelevitz, USA

07:50 - 08:00    **Discussion**

**Session II: Future Integration of Biomarkers in the Selection of High Risk Individuals for Lung Cancer Screening**

08:00 - 08:50    **The U19 Plans for Integration of Biomarkers into Future Lung Cancer Screening**

Rayjean Hung, Canada; Chris Amos, USA; Paul Brennan, France

08:50 - 09:00    **Discussion**

**Session III: European Strategy for the Implementation of Lung Cancer Screening**

09:00 - 09:20    **EU Position Statement on Lung Cancer Screening**

Matthijs Oudkerk, Netherlands

09:20 - 09:30    **Discussion**

09:30 - 09:50    **Coffee break**

**Session IV: Lung Cancer Screening Requires Infra-Structural Organisation and an Integrated Smoking Cessation Plan**

09:50 - 10:05    **Coordination of the Lung Cancer CT Screening Experience**

Joelle Fathi, Sweden

10:05 - 10:20    **Integration of Smoking Cessation into Lung Cancer Screening**

Kate Brain, UK

10:20 - 10:30    **Discussion**



- 10:30 - 11:30 **Session V: Panel Discussion: Next Steps for Lung Screening?**  
Claudia Henschke, USA; Kwun Fong, Australia; Sheila Ross, USA; Motoyasu Sagawa, Japan; Matthew Callister, UK; Nasser Altorki, USA; Bruce Pyenson, USA
- 11:30 - 11:50 **Session VI - IASLC Leads the International Collaboration on Data Sharing (CCTRR)**  
John Field, UK; James Mulshine, USA
- 11:50 - 12:00 **Discussion**
- 12:00 - 12:00 **Networking Lunch**

## JCSE01

**07:30 - 11:45** **Type: Joint IASLC/CSCO/CAALC Session**  
**Title: Perspectives for Lung Cancer Early Detection**  
Track: Screening and Early Detection  
Moderation: Fred Hirsch, USA; Yi-long Wu, China; Tony Mok, Hong Kong; ChunXue Bai; China

- 07:30 - 08:00 **JCSE01.01 - Breakfast and Poster Viewing**
- 08:00 - 08:20 **JCSE01.02 - Necessity for Early Detection in Lung Cancer and Initial Attempts for Early Detection**  
Annette McWilliams, Australia
- 08:20 - 08:40 **JCSE01.03 - CT Screening for Early Detection (NLST, UKLS, NELSON, ITALUNG, DANTE, Others)**  
Matthijs Oudkerk, Netherlands
- 08:40 - 09:00 **JCSE01.04 - Risk Modeling for the Early Detection of Tin Miner Lung Cancer in China**  
You-lin Qiao, China
- 09:00 - 09:20 **JCSE01.05 - Biomarkers and Liquid Biopsy for Early Detection of Lung Cancer**  
Allen Chan, China
- 09:20 - 09:40 **JCSE01.06 - Incorporating Artificial Intelligence for Early Detection of Lung Cancer**  
Jie Hu, China
- 09:40 - 10:00 **JCSE01.07 - Cost Effectiveness and Economic Implication of Lung Cancer Early Detection**  
Gilberto De Lima Lopes, USA
- 10:00 - 10:20 **JCSE01.08 - Coffee Break and Poster Viewing**
- 10:20 - 10:35 **JCSE01.09 - Abstract Presentation from China Related to Early Detection (1)**
- 10:35 - 10:50 **JCSE01.10 - Abstract Presentation from China Related to Early Detection (2)**
- 10:50 - 11:05 **JCSE01.11 - Abstract Presentation from China Related to Early Detection (3)**
- 11:05 - 11:25 **JCSE01.12 - Discussant Oral Abstracts**
- 11:25 - 11:45 **JCSE01.13 - Discussant Poster Abstracts**
- 11:45 - 11:45 **JCSE01.14 - Closing Remarks**



## ISS01

**09:45 - 11:15** Type: Industry Supported Symposia  
Title: Symposium Supported by Takeda: New Insights and Clinical Implications for the Treatment of ALK+ NSCLC

## ISS02

**11:30 - 13:00** Type: Industry Supported Symposia  
Title: Symposium Supported by Incyte: Novel Immunotherapy Strategies in Lung Cancer

## ISS03

**13:00 - 14:30** Type: Industry Supported Symposia  
Title: Symposium Supported by Lilly Oncology: Driving Improved Outcomes in Non-driver Mutation Lung Cancer: The Challenges and Progress

## ISS04

**14:30 - 16:00** Type: Industry Supported Symposia  
Title: Symposium Supported by Bristol-Myers Squibb

## ISS05

**16:00 - 17:30** Type: Industry Supported Symposia  
Title: Symposium Supported by AstraZeneca

## PR01

**16:00 - 17:30** Type: Press Conference  
Title: Press Conference

**17:45 - 18:45** Type: Networking Opportunity  
Title: IASLC Foundation Concert (Ticketed Event)

## OC01

**19:00 - 20:30** Type: Opening Ceremony  
Title: Opening Ceremony

**19:00 - 19:10** OC01.01 - Eradicating Lung Cancer  
Prabat Jha, Canada

**19:10 - 19:20** OC01.02 - Tobacco Free World  
Bronwyn King, Australia

**20:30 - 22:00** Type: Networking Opportunity  
Title: Welcome Reception



## Monday, September 24, 2018

### ISS06

07:00 - 08:00 Type: Industry Supported Symposia  
Title: Symposium Supported by Medscape

### MTE01

07:00 - 08:00 Type: Meet the Expert  
Title: Preclinical Models of Lung Cancer (Ticketed Session)

Track: Biology

07:00 - 07:30 MTE01.01 - GEMM of Lung Cancer  
Sarah Best, Australia

07:30 - 08:00 MTE01.02 - Lung PDX and Organoids

### MTE02

07:00 - 08:00 Type: Meet the Expert  
Title: Update on WHO Classification and Staging of Lung Cancer (Ticketed Session)

Track: Pathology

07:00 - 07:30 MTE02.01 - Update on WHO Classification and Staging of Lung Cancer  
Sanja Dacic, USA

07:30 - 08:00 MTE02.02 - Update on WHO Classification and Staging of Lung Cancer  
Teh-Ying Chou, Taiwan

### MTE03

07:00 - 08:00 Type: Meet the Expert  
Title: Clinical Trial Design With Novel Lung Cancer Therapy (Ticketed Session)

Track: Targeted Therapy

07:00 - 07:30 MTE03.01 - Inclusion/Exclusion Updates (CNS Mets, Multiple Prior Cancers, Organ Dysfunction)  
Peter Ellis, Canada

07:30 - 08:00 MTE03.02 - Novel Trial Design for Precision Medicine  
Fiona Blackhall, UK



## MTE04

**07:00 - 08:00** Type: Meet the Expert  
Title: Comparison of Various Risk Models (Ticketed Session)  
Track: Screening and Early Detection

07:00 - 07:30 **MTE04.01 - Comparisons of Risk Models**  
Christine Berg, USA

07:30 - 08:00 **MTE04.02 - Where Should Health Programs Set Threshold for Tailored Screening?**  
James Mulshine, USA

## MTE05

**07:00 - 08:00** Type: Meet the Expert  
Title: Role of Pneumonectomy in N2 Disease (Ticketed Session)  
Track: Treatment of Locoregional Disease - NSCLC

07:00 - 07:30 **MTE05.01 - Role of Pneumonectomy in N2 Disease**  
Jessica Donington, USA

07:30 - 08:00 **MTE05.02 - Role of Pneumonectomy in N2 Disease**  
Paula Ugalde, Canada

## MTE06

**07:00 - 08:00** Type: Meet the Expert  
Title: Symptom Management in Mesothelioma (Ticketed Session)  
Track: Mesothelioma

07:00 - 07:30 **MTE06.01 - Role of Pleurectomy in Palliation of Symptoms**  
John Edwards, UK

07:30 - 08:00 **MTE06.02 - How to Register Toxicity and Guide Patients**  
Liz Darlison, UK

## MTE07

**07:00 - 08:00** Type: Meet the Expert  
Title: Management of Pleural Recurrence (Ticketed Session)  
Track: Thymoma/Other Thoracic Malignancies

07:00 - 07:30 **MTE07.01 - From Radiation Oncology Perspective**  
Andreas Rimner, USA

07:30 - 08:00 **MTE07.02 - Debate on Standard Surgical Approaches - Minimally Invasive Thymectomy**  
Robert Korst, USA



## MTE08

**07:00 - 08:00** Type: Meet the Expert  
 Title: Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges (Ticketed Session)  
 Track: Nursing and Allied Professionals

**07:00 - 08:00** MTE08.01 - Enhancing the Nurse's Role in Tobacco Prevention and Cessation: New Challenges  
 Linda Sarna, USA

## MTE09

**07:00 - 08:00** Type: Meet the Expert  
 Title: Management of Advanced Wild-Type Lung Cancer in Special Situations (Ticketed Session)  
 Track: Advanced NSCLC

**07:00 - 07:30** MTE09.01 - Evidence Based Management of the Patient over 80  
 Elisabeth Quoix, France

**07:30 - 08:00** MTE09.02 - Management of the PS 2 Patient  
 Joan Schiller, USA

## MTE10

**07:00 - 08:00** Type: Meet the Expert  
 Title: Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous (Ticketed Session)  
 Track: Interventional Diagnostics/Pulmonary

**07:00 - 08:00** MTE10.01 - Emerging Technologies for Small and Smaller Lesions - Update on Ablation via Endoscopy vs Percutaneous  
 Felix Herth, Germany

## PL01

**08:15 - 09:45** Type: Plenary Session  
 Title: Patients First  
 Moderation: Andrea Bezjak, Canada; Paul Bunn Jr., USA

**08:15 - 08:25** PL01.01 - When Breath Becomes Air

**08:25 - 08:40** PL01.02 - Science that Matters  
 David Carbone, USA

**08:40 - 08:55** PL01.03 - Trials that Matter!  
 Tony Mok, Hong Kong





08:55 - 09:10 **PL01.04 - Getting Drugs to Patients Faster: A Global View**

Solange Peters, Switzerland

09:10 - 09:25 **PL01.05 - Conquering Lung Cancer - The IASLC Vision**

Giorgio Scagliotti, Italy

09:25 - 09:40 **PL01.06 - Patients First**

Tish Vigna, Canada

09:45 - 10:30 **Type: Poster Viewing**  
**Title: Poster Viewing - Exhibit Hall**

#### MS01

10:30 - 12:00 **Type: Mini Symposium**  
**Title: Cancer Pathways, Targeted Therapy and Resistance**

Track: Biology  
Moderation: Greg Riely, USA

10:30 - 10:50 **MS01.01 - Swi/Snf: Pathways Beyond the RTK/Ras/Raf Pathway**

Montse Sanchez-Cespedes, Spain

10:50 - 11:10 **MS01.02 - Targeting Negative Feedback Regulators to Hyperactivate Oncogenic Signaling**

Will Lockwood, Canada

11:10 - 11:30 **MS01.03 - Stimulating Anti-Tumor Immunity Through Enhancing T-Cell Activation**

Kwok-Kin Wong, USA

11:30 - 11:50 **MS01.04 - Discussant**

Robert Doebele, USA

11:50 - 12:00 **MS01.05 - Q&A**

#### MS02

10:30 - 12:00 **Type: Mini Symposium**  
**Title: The Future of IO**

Track: Immunology  
Moderation: Yuichiro Ohe, Japan; Rina Hui, Australia

10:30 - 10:45 **MS02.01 - What Is/Will Be the Optimal Duration of Therapy with IO?**

David Spigel, USA

10:45 - 11:00 **MS02.02 - Combination Therapies: Where Are We in 2018?**

Martin Reck, Germany

11:00 - 11:15 **MS02.03 - Next Generation IO in Lung Cancer**

Solange Peters, Switzerland



11:15 - 11:30 **MS02.04 - Optimizing Clinical Trial Designs in Immunotherapy**

Vassiliki Papadimitrakopoulou, USA

11:30 - 11:45 **MS02.05 - Convincing Policy Makers to Afford Immunotherapy**

Carlos Gil Ferreira, Brazil

11:45 - 12:00 **MS02.06 - Q&A**

### MS03

10:30 - 12:00

**Type: Mini Symposium**

**Title: New Frontiers in Oligometastases**

Track: Oligometastatic NSCLC

Moderation: Jyoti Patel, USA; Eric Lim, UK

10:30 - 10:45 **MS03.01 - The Biology of Oligometastases: What Have We learned?**

David Palma, Canada

10:45 - 11:00 **MS03.02 - Biomarkers in Oligometastatic Patients i. Monitoring Diseases Response - Imaging vs Serum**

Max Diehn, USA

11:00 - 11:15 **MS03.03 - Investigations into Alternative Clinical Endpoints for OM Beyond Survival**

Alexander Louie, Canada

11:15 - 11:30 **MS03.04 - Treatment of Oligoprogression: Real Progress or False Hope?**

Fiona McDonald, UK

11:30 - 11:45 **MS03.05 - Integration of Immunotherapy in the Oligometastatic Paradigm**

Shankar Siva, Australia

11:45 - 12:00 **MS03.06 - Q&A**

### MS04

10:30 - 12:00

**Type: Mini Symposium**

**Title: Joint GLCC/IASLC Session: Exploring Hot Topics for Advocates**

Track: Advocacy

Moderation: Carolyn Aldige, USA; Paul, Wheatley-Price, Canada

10:30 - 10:45 **MS04.01 - Collecting Data in the Real World - How Can Patient Groups Work with Researchers in Defining and Collecting Real-World Evidence?**

Taofeek Owonikoko, USA

10:45 - 11:00 **MS04.02 - How Is Lung Cancer Screening Evolving to Be More Efficient and Effective?**

David Baldwin, UK

11:00 - 11:15 **MS04.03 - Exploring Smoking Stigma, Negativity and Lung Cancer - What Can Be Done?**

Stefania Vallone, Italy





11:15 - 11:30 **MS04.04 - E-Cigarettes - What Do Lung Cancer Advocates Need to Know?**

Matthew Peters, Australia

11:30 - 12:00 **MS04.05 - Panel Discussion**

#### PC01

**10:30 - 12:00** Type: Pro-Con Session  
Title: Controversies in Mesothelioma

Track: Mesothelioma

Moderation: Nicole Bouchard, Canada; Nico Van Zandwijk, Australia

10:30 - 10:45 **PC01.01 - PRO Intrapleural Chemotherapy Is It the Future?**

Isabelle Schmitt-Opitz, Switzerland

10:45 - 11:00 **PC01.02 - CON Intrapleural Chemotherapy Is It the Future?**

11:00 - 11:15 **PC01.03 - PRO IO in Mesothelioma Should Only Be Given on Clinical Trials**

Penny Bradbury, Canada

11:15 - 11:30 **PC01.04 - CON in Mesothelioma Should Only Be Given on Clinical Trials**

Evan Alley, USA

11:30 - 11:45 **PC01.05 - PRO Radiation Options: Are We SMART Enough?**

John Cho, Canada

11:45 - 12:00 **PC01.06 - CON Radiation Options: Are We SMART Enough?**

Charles Simone, USA

#### ISS07

**12:00 - 13:30** Type: Industry Supported Symposia  
Title: Symposium Supported by Merck

#### JTO

**12:00 - 13:30** Type: Meet the Editor  
Title: Meet the JTO Editor

Moderation: Alex Adjei, USA

12:00 - 13:30 **JTO.01 - Meet the JTO Editor**

Alex Adjei, USA



## ES01

13:30 - 15:00

**Type: Educational Session**  
**Title: Advances in Lung Cancer Screening Through Imaging**

Track: Screening and Early Detection  
 Moderation: Heidi Schmidt, Canada; Denise Aberle, USA

13:30 - 13:50

**ES01.01 - Image Quality Characteristics and Nodule Growth Measurement, Medical Physics and Machine Parameters**

Ricardo Avila, USA

13:50 - 14:10

**ES01.02 - Image Interpretation and Advances from the Perspective of the Radiologist**

David Yankelevitz, USA

14:10 - 14:30

**ES01.03 - Deep Machine Learning for Screening LDCT**

Bram Van Ginneken, Netherlands

14:30 - 14:50

**ES01.04 - Multi-Phasic Screening - Can We Address Competing Causes of Morbidity \* Mortality Such as Coronary Artery Disease and COPD and How to Manage Incidental Findings**

Rozemarijn Vliegenthart, Netherlands

14:50 - 15:00

**ES01.05 - Q&A**

## MS05

13:30 - 15:00

**Type: Mini Symposium**  
**Title: Diagnostic Dilemma in Lung Cancer**

Track: Pathology  
 Moderation: David Hwang, Canada; Johan Botling, Sweden

13:30 - 13:50

**MS05.01 - Staging and Pathology of Multiple Lung Nodules**

Alain Borczuk, USA

13:50 - 14:10

**MS05.02 - Defining Invasion in Minimally Invasive Adenocarcinoma**

Masayuki Noguchi, Japan

14:10 - 14:30

**MS05.03 - Tumor Heterogeneity in Lung Cancer**

Elisabeth Brambilla, France

14:30 - 14:50

**MS05.04 - Diagnosis and Classification in Biopsies**

Andre Moreira, USA

14:50 - 15:00

**MS05.05 - Q&A**



## MS06

13:30 - 15:00

**Type: Mini Symposium****Title: Practical Issues in the Management of Oligometastatic NSCLC**

Track: Oligometastatic NSCLC

Moderation: Mary Macneil, Canada; Ugo Pastorino, Italy

13:30 - 13:45

**MS06.01 - The Role of Radiation in Treating the Primary and Mets**

Hak Choy, USA

13:45 - 14:00

**MS06.02 - The Role of Interventional Pulmonology and Radiology**

Kwun Fong, Australia

14:00 - 14:15

**MS06.03 - The Role of Surgical Resection**

Boris Sepesi, USA

14:15 - 14:30

**MS06.04 - Systemic Therapy for Oligomets: Before, During, or After Local Therapies?**

Ross Camidge, USA

14:30 - 14:45

**MS06.05 - The Special Case of Brain Metastases: Systemic Therapy, Radiation or Both?**

Laurie Gaspar, USA

14:45 - 15:00

**MS06.06 - Q&A**

## MS07

13:30 - 15:00

**Type: Mini Symposium****Title: Antibody-Drug Conjugates in Advanced NSCLC**

Track: Advanced NSCLC

Moderation: Normand Blais, Canada; Rebecca Heist, USA

13:30 - 13:50

**MS07.01 - Basic Science**

David Gerber, USA

13:50 - 14:10

**MS07.02 - Pharmacology**

Christian Rolfo, Belgium

14:10 - 14:30

**MS07.03 - Clinical Data**

Thomas Stinchcombe, USA

14:30 - 14:50

**MS07.04 - Future Directions**

Silvia Novello, Italy

14:50 - 15:00

**MS07.05 - Q&A**



## MS08

- 13:30 - 15:00**    **Type: Mini Symposium**  
**Title: Lung Cancer in the Real World**
- Track: Treatment in the Real World - Support, Survivorship, Systems Research  
Moderation: Antonia Wozniak, USA; Ronan Kelly, USA
- 13:30 - 13:50**    **MS08.01 - How Can Real World Data Improve Clinical Evidence Generation and Impact Regulatory Bodies**  
Yolande Lievens, Belgium; Gideon Blumenthal, USA
- 13:50 - 14:05**    **MS08.02 - Sources of Real World Data: Research Designs, Statistical Modelling and Quality Assurance Requirements**  
Mary Redman, USA
- 14:05 - 14:20**    **MS08.03 - The ASCO Perspective**  
Bruce Johnson, USA
- 14:20 - 14:35**    **MS08.04 - The ESTRO Perspective**  
Umberto Ricardi, Italy
- 14:35 - 15:00**    **MS08.05 - Discussion**

## PC02

- 13:30 - 15:00**    **Type: Pro-Con Session**  
**Title: Debate on Local Therapies for Limited Small Cell Lung Cancer? Surgery PRO/CON and BID Radiation PRO/CON**
- Track: Small Cell Lung Cancer/NET  
Moderation: Quincy Chu, Canada; Wilfried Eberhardt, Germany
- 13:30 - 13:50**    **PC02.01 - Surgery - PRO**  
Elliot Wakeam, Canada
- 13:50 - 14:10**    **PC02.02 - Surgery - CON**  
Cecile Le Pechoux, France
- 14:10 - 14:30**    **PC02.03 - BID Radiation - CON**  
Ben Slotman, Netherlands
- 14:30 - 14:50**    **PC02.04 - BID Radiation - PRO**  
Jeffrey Bogart, USA
- 14:50 - 15:00**    **PC02.05 - Q&A**



## MS09

**15:15 - 16:45**    **Type: Mini Symposium**  
**Title: Tumour Board - Tissue Acquisition and Staging**  
 Track: Interventional Diagnostics/Pulmonary  
 Moderation: Septimiu Murgu, USA; Eric Edell, USA

15:15 - 15:35    **MS09.01 - Cases Prepared by Drs. Edell/Murgu**  
 Neal Navani, UK

15:35 - 15:55    **MS09.02 - Cases Prepared by Drs. Edell/Murgu**  
 Karin Steinke, Australia

15:55 - 16:15    **MS09.03 - Cases Prepared by Drs. Edell/Murgu**  
 Kazuhiro Yasufuku, Canada

16:15 - 16:35    **MS09.04 - Cases Prepared by Drs. Edell/Murgu**

16:35 - 16:45    **MS09.05 - Q&A**

## MS10

**15:15 - 16:45**    **Type: Mini Symposium**  
**Title: Part Solid Nodules, GGN and STAS**  
 Track: Treatment of Early Stage/Localized Disease  
 Moderation: Paul Van Schil, Belgium; Nir Peled, Israel

15:15 - 15:30    **MS10.01 - Radiographic Differences Between Presumed AIS and MIA**  
 Mini Pakkal, Canada

15:30 - 15:45    **MS10.02 - Importance of CT in the Pathologic Assessment of Tumor Sized in Subsolid and Part-Solid Adenocarcinoma**

15:45 - 16:00    **MS10.03 - CT Versus Needle Biopsy Assessment Before Resection of Part Solid Nodules**  
 Young Tae Kim, Korea

16:00 - 16:15    **MS10.04 - Therapeutic Implications of Spread Through Air Spaces (STAS)**  
 William Travis, USA

16:15 - 16:30    **MS10.05 - Should We Resect GGNs**  
 Kenji Suzuki, Japan

16:30 - 16:45    **MS10.06 - Q&A**



## MS11

- 15:15 - 16:45**    **Type: Mini Symposium**  
**Title: Stigma and Lung Cancer: Unintended Translational Consequences of Effective Tobacco Control**
- Track: Prevention and Tobacco Control  
Moderation: Antoni Rosell, Spain; Li Zhang, China
- 15:15 - 15:35**    **MS11.01 - Identifying Consequences of Stigma on Lung Cancer Care Delivery and Patient Outcomes**  
Heidi Hamann, USA
- 15:35 - 15:55**    **MS11.02 - Stigma of Tobacco and Lung Cancer: A South American Perspective**
- 15:55 - 16:15**    **MS11.03 - Prevalence of Perceived Lung Cancer Stigma Among Medical and Nursing Students**  
Jamie Studts, USA
- 16:15 - 16:35**    **MS11.04 - Taking a Smoking History in the Context of Lung Cancer Treatment: Missed Opportunities for Stigma-Reducing Empathic Encounters with Throacic Oncologists**  
Peter Harper, UK
- 16:35 - 16:45**    **MS11.05 - Q&A**

## MS12

- 15:15 - 16:45**    **Type: Mini Symposium**  
**Title: Immunotherapy and RT**
- Track: Treatment of Locoregional Disease - NSCLC  
Moderation: Yi-long Wu, China; Salama Joseph, USA
- 15:15 - 15:35**    **MS12.01 - Biology IO+RT**  
Dirk De Ruyscher, Netherlands
- 15:35 - 15:55**    **MS12.02 - Clinical Data Available**  
Feng-Ming (Spring) Kong, USA
- 15:55 - 16:15**    **MS12.03 - Ongoing Studies**  
Francoise Mornex, France
- 16:15 - 16:35**    **MS12.04 - Implications for Routine Practice**  
Paul Mitchell, Australia
- 16:35 - 16:45**    **MS12.05 - Q&A**





## PC03

15:15 - 16:45

**Type: Pro-Con Session**  
**Title: Controversies in Management of Resectable Thymoma**

Track: Thymoma/Other Thoracic Malignancies  
 Moderation: Norihiko Ikeda, Japan; Andrea Bezjak, Canada

15:15 - 15:25

**PC03.01 - Post-Operative Radiation Therapy or NOT: PRO**  
 Conrad Falkson, Canada

15:25 - 15:35

**PC03.02 - Post-Operative Radiation Therapy or NOT: CON**  
 Daniel Gomez, USA

15:35 - 15:45

**PC03.03 - Discussion**

15:45 - 15:55

**PC03.04 - From Surgical Perspective**  
 Shaf Keshavjee, Canada

15:55 - 16:05

**PC03.05 - Debate on Standard Surgical Approaches - Open Thymectomy**  
 Meinoshin Okumura, Japan

16:05 - 16:15

**PC03.06 - Discussion**

16:15 - 16:25

**PC03.07 - Adjuvant Chemotherapy for Thymic Carcinoma - YES**  
 Giulia Pasello, Italy

16:25 - 16:35

**PC03.08 - Adjuvant Chemotherapy for Thymic Carcinoma - NO**  
 Sukhmani Padda, USA

16:35 - 16:45

**PC03.09 - Discussion**

## PC04

15:15 - 16:45

**Type: Pro-Con Session**  
**Title: Targeted Therapy for NSCLC**

Track: Targeted Therapy  
 Moderation: Zosia Piotrowska, USA; Ben Solomon, Australia

15:15 - 15:27

**PC04.01 - Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)**  
 James Chih-Hsin Yang, Taiwan

15:27 - 15:39

**PC04.02 - Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First**  
 Karen Reckamp, USA

15:39 - 15:51

**PC04.03 - Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes**  
 Shun Lu, China

15:51 - 16:03

**PC04.04 - Adjuvant Targeted Therapy for pts with Genomic Alterations - No**  
 Lecia Sequist, USA



16:03 - 16:15 **PC04.05 - NGS/Whole Exome Sequencing for Routine Use**  
Daniel Tan, Singapore

16:15 - 16:27 **PC04.06 - Focused Panels for Molecular Profiling for Routine Use**

16:27 - 16:45 **PC04.07 - Q&A**

16:45 - 18:00 **Type: Poster Viewing**  
**Title: Poster Viewing Reception in the Exhibit Hall**

ISS08

18:00 - 19:30 **Type: Industry Supported Symposia**  
**Title: Symposium Supported by Boehringer Ingelheim**

20:00 - 22:30 **Type: Networking Opportunity**  
**Title: Faculty Dinner (By Invitation Only)**



## Tuesday, September 25, 2018

### ISS09

07:00 - 08:00 Type: Industry Supported Symposia  
Title: Symposium Supported by Roche

### ISS10

07:00 - 08:00 Type: Industry Supported Symposia  
Title: Symposium Supported by Medscape: Progressing the Revolution in NSCLC: Questioning the Experts

### ISS11

07:00 - 08:00 Type: Industry Supported Symposia  
Title: Symposium Supported by Pfizer

### MTE11

07:00 - 08:00 Type: Meet the Expert  
Title: Biology of Small Cell Lung Cancer (Ticketed Session)  
Track: Biology

07:00 - 07:30 MTE11.01 - Notch Signaling  
Julien Sage, USA

07:30 - 08:00 MTE11.02 - MYC-Driven SCLC  
Charles Rudin, USA

### MTE12

07:00 - 08:00 Type: Meet the Expert  
Title: IO in the Real World - High Risk Populations And Patient Support (Ticketed Session)  
Track: Immunocology

07:00 - 07:40 MTE12.01 - Is IO an Option for Patients with Contraindications (Auto-immune Disease, Pulmonary Fibrosis, HIV, Hepatitis, Transplant etc)  
Andrew Robinson, Canada

07:40 - 08:00 MTE12.02 - How can we Minimize Toxicity for our High Risk Patients?  
Massey Nematollahi, Canada



## MTE13

**07:00 - 08:00** Type: Meet the Expert  
Title: Clonal Evolution and Targeted Therapy (Ticketed Session)  
Track: Targeted Therapy

07:00 - 07:30 MTE13.01 - Clonal Evolution and Targeted Therapy  
Ramaswamy Govindan, USA

07:30 - 08:00 MTE13.02 - Clonal Evolution and Targeted Therapy  
Janessa Laskin, Canada

## MTE14

**07:00 - 08:00** Type: Meet the Expert  
Title: Nodule Management (Pro Con Debate and Case Presentations) (Ticketed Session)  
Track: Screening and Early Detection

07:00 - 07:30 MTE14.01 - Nodule Management (Pro Con Debate and Case Presentations)  
Stephen Lam, Canada

07:30 - 08:00 MTE14.02 - Nodule Management (Pro Con Debate and Case Presentations)  
Matthijs Oudkerk, Netherlands

## MTE15

**07:00 - 08:00** Type: Meet the Expert  
Title: Who is Too High Risk for a VATS Resection? (Ticketed Session)  
Track: Treatment of Early Stage/Localized Disease

07:00 - 07:30 MTE15.01 - Identifying High Risk Patients: What Makes a Patient Too High Risk for Surgery and Who Decides?  
Hisao Asamura, Japan

07:30 - 08:00 MTE15.02 - Who is Too High Risk for a VATS Resection?  
Pieter E Postmus, UK

## MTE16

**07:00 - 08:00** Type: Meet the Expert  
Title: How I Treat Advanced Stage Thymic Malignancy Patients (Ticketed Session)  
Track: Thymoma/Other Thoracic Malignancies

07:00 - 08:00 MTE16.01 - How I Treat Advanced Stage Thymic Malignancy Patients  
Heather Wakelee, USA



## MTE17

**07:00 - 08:00** Type: Meet the Expert  
 Title: Living with and Beyond Lung Cancer: An Education for Advocates (Ticketed Session)  
 Track: Advocacy

07:00 - 08:00 MTE17.01 - Living with and Beyond Lung Cancer: An Education for Advocates  
 Aoife Mc Namara, Ireland; Winfield Boerckel, USA

## MTE18

**07:00 - 08:00** Type: Meet the Expert  
 Title: Case-Based Management of Patients with Inadequate Tissue for Molecular Tests (Ticketed Session)  
 Track: Advanced NSCLC

07:00 - 07:30 MTE18.01 - Case-Based Management of Patients with Inadequate Tissue for Molecular Tests  
 Benjamin Levy, USA

07:30 - 08:00 MTE18.02 - Case-Based Management of Patients with Inadequate Tissue for Molecular Tests  
 Adrian Sacher, Canada

## MTE19

**07:00 - 08:00** Type: Meet the Expert  
 Title: What Is Changing in the Management of Pulmonary Neuroendocrine Tumours? (Ticketed Session)  
 Track: Small Cell Lung Cancer/NET

07:00 - 07:30 MTE19.01 - Proper Treatment of LCNEC; Chemotherapy or Targeted Therapy  
 Sumitra Thongprasert, Thailand

07:30 - 08:00 MTE19.02 - The Management of Small Cell Lung Cancer following First Line Treatment Failure  
 Glenwood Goss, Canada

## SH01

**07:00 - 08:00** Type: Scientific Highlights  
 Title: Highlight of the Previous Day Sessions

## PL02

**08:15 - 09:45** Type: Plenary Session  
 Title: Presidential Symposium - Top 4 Abstracts  
 Moderation: Frances Shepherd, Canada; Giorgio, Scagliotti, Italy; Ming Tsao, Canada



09:45 - 10:30 **Type: Poster Viewing**  
**Title: Poster Viewing - Exhibit Hall**

## ES02

10:30 - 12:00 **Type: Educational Session**  
**Title: Quality Care in Lung Cancer**  
Track: Nursing and Allied Professionals  
Moderation: Pippa Labuc, UK; Nazanin Nouriany, Canada

10:30 - 10:45 **ES02.01 - Expanding PROs in Daily Practice**  
Kahren White, Australia

10:45 - 11:00 **ES02.02 - PRO: To Medicate: Managing Breathlessness**  
Alexandre Chan, Singapore

11:00 - 11:15 **ES02.03 - CON: Not to Medicate: Managing Breathlessness**  
Catherine Granger, Australia

11:15 - 11:30 **ES02.04 - Molecular Testing 101 for Nurses**  
Beth Ebay-Sandy, USA

11:30 - 11:45 **ES02.05 - Structured Approach For Developing and Implementing and Advanced Practice Nursing Role in Lung Cancer**  
Andrea Serena, Switzerland

11:45 - 12:00 **ES02.06 - Q&A**

## GR01

10:30 - 12:00 **Type: Grand Rounds**  
**Title: Thymic Malignancies Tumor Board**  
Track: Thymoma/Other Thoracic Malignancies  
Moderation: Vincent (Wentao) Fang, China; Giuseppe Giaccone, USA

10:30 - 10:45 **GR01.01 - Pathology**  
Anja Roden, USA

10:45 - 11:00 **GR01.02 - Surgical Oncology**  
Pier Luigi Filosso, Italy

11:00 - 11:15 **GR01.03 - Surgical Oncology**  
David Waller, UK

11:15 - 11:30 **GR01.04 - Medical Oncology**  
Nicolas Girard, France

11:30 - 11:45 **GR01.05 - Radiation Oncology**  
Anthony Brade, Canada

11:45 - 12:00 **GR01.06 - Discussion**





## MS13

10:30 - 12:00

**Type: Mini Symposium**  
**Title: Novel Mediators of Lung Cancer Metastasis**

Track: Biology  
 Moderation: Oscar Arrieta, Mexico

10:30 - 10:45

**MS13.01 - CD109-Janus kinase-Stat Axis as a Target for Metastatic Lung Cancer**

10:45 - 11:00

**MS13.02 - Capicua Inactivation Drives Lung Cancer Metastasis**

Trevor Bivona, USA

11:00 - 11:15

**MS13.03 - Ubiquilin as a Novel Mediator of Lung Cancer Invasion and Metastasis**

Levi Beverly, USA

11:15 - 11:30

**MS13.04 - Tracking the Evolution of Non-Small-Cell Lung Cancer**

11:30 - 11:45

**MS13.05 - Discussant**

David Beer, USA

11:45 - 12:00

**MS13.06 - Q&A**

## MS14

10:30 - 12:00

**Type: Mini Symposium**  
**Title: IO in Early Stage NSCLC**

Track: Immunocology  
 Moderation: Mark Kris, USA

10:30 - 10:45

**MS14.01 - Basic Science Rationale of IO in Early Stage NSCLC?**

Johan Vansteenkiste, Belgium

10:45 - 11:00

**MS14.02 - Adjuvant / Neoadjuvant IO Therapy**

Julie Brahmer, USA

11:00 - 11:15

**MS14.03 - Concerns About IO for the Thoracic Surgeon?**

Bernward Passlick, Germany

11:15 - 11:30

**MS14.04 - IO - New Standards in Stage III NSCLC**

Rafal Dziadziuszko, Poland

11:30 - 11:45

**MS14.05 - Do Biomarkers used in Metastatic Setting Apply in Earlier Stages**

Naiyer Rizvi, USA

11:45 - 12:00

**MS14.06 - Q&A**



## MS15

|                      |   |
|----------------------|---|
| <b>10:30 - 12:00</b> | <b>Type: Mini Symposium</b><br><b>Title: Disruptive Technology and Lung Cancer Risk</b><br>Track: Prevention and Tobacco Control<br>Moderation: Eric Bedard, Canada; Doug Arenberg, USA |
| 10:30 - 10:45        | <b>MS15.01 - Just Water Vapor? Toxicology Perspectives on Electronic Cigarettes</b><br>Maciej Goniewicz, USA  |
| 10:45 - 11:00        | <b>MS15.02 - PRO- Electronic Cigarettes: A Cessation Tool</b><br>K Michael Cummings, USA  |
| 11:00 - 11:15        | <b>MS15.03 - CON- Electronic Cigarettes: Not Evidence Based Cessation</b><br>Alison Wallace, Canada   |
| 11:15 - 11:30        | <b>MS15.04 - The Rise of Heat-Not Burn Tobacco in Japan: A “Hot” Issue for Tobacco Control</b><br>Junji Yoshida, Japan  |
| 11:30 - 11:45        | <b>MS15.05 - Heat-Not-Burn Tobacco: Real Risk Reduction or Industry’s Next Promise</b><br>Carolyn Dresler, USA  |
| 11:45 - 12:00        | <b>MS15.06 - Q&amp;A</b>  |

## PC05

|                      |  |
|----------------------|--|
| <b>10:30 - 12:00</b> | <b>Type: Pro-Con Session</b><br><b>Title: Optimizing Clinical Trial Design in NSCLC</b><br>Track: Advanced NSCLC<br>Moderation: Pilar Garrido, Spain           |
| 10:30 - 10:45        | <b>PC05.01 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: PFS</b><br>Mary O’Brien, UK |
| 10:45 - 11:00        | <b>PC05.02 - Debate 1: Which is Most Important Efficacy Endpoint in First Line Trials in Advanced NSCLC PFS or OS - Point of View: OS</b><br>Yu Shyr, USA      |
| 11:00 - 11:05        | <b>PC05.03 - Discussion</b>  |
| 11:05 - 11:20        | <b>PC05.04 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - YES</b><br>Maurice Pérol, France  |
| 11:20 - 11:35        | <b>PC05.05 - Debate 2: Patient Reported Outcomes Should Be the Most Important Endpoint in Trials in the Palliative Setting - NO</b><br>Rathi Pillai, USA       |



- 11:35 - 11:40      **PC05.06 - Discussion**
- 11:40 - 11:50      **PC05.07 - Let's Not Forget Chemo-Regret**  
Patricia Hollen, USA
- 11:50 - 12:00      **PC05.08 - Discussion**

## ISS12

- 12:00 - 13:30**      **Type: Industry Supported Symposia**  
**Title: Symposium Supported by Novartis: Expert Perspectives on the Management of NSCLC in Clinical Practice: Are Novel Approaches Realistic?**

## MS16

- 13:30 - 15:00**      **Type: Mini Symposium**  
**Title: Implementation of Lung Cancer Screening**  
Track: Screening and Early Detection  
Moderation: Garth Nicholas, Canada; Harry Groen, Netherlands

- 13:30 - 13:45      **MS16.01 - CMS Approved ACR Lung Cancer Screening Registry in the United States**  
Ella Kazerooni, USA
- 13:45 - 14:00      **MS16.02 - NELCIN B3 Screening Program in China**  
Qinghua Zhou, China
- 14:00 - 14:15      **MS16.03 - Population Screening - Canadian Pilot Program in Ontario**  
Gail Darling, Canada
- 14:15 - 14:30      **MS16.04 - National Lung Screening Program in Taiwan**  
Pan-Chyr Yang, Taiwan
- 14:30 - 14:45      **MS16.05 - Optimal Approach to Integrate Smoking Cessation into Screening Program**  
Matthew Callister, UK
- 14:45 - 15:00      **MS16.06 - Q&A**

## MS17

- 13:30 - 15:00**      **Type: Mini Symposium**  
**Title: Life After Lung Cancer: Survivorship**  
Track: Treatment in the Real World - Support, Survivorship, Systems Research  
Moderation: David Dawe, Canada; Martin Stockler, Australia

- 13:30 - 13:45      **MS17.01 - Unmet needs and QOL of Lung Cancer Survivors**  
Meredith Giuliani, Canada
- 13:45 - 14:00      **MS17.02 - Financial Toxicity and Out of Pocket Costs**



Bishal Gyawali, Nepal

- 14:00 - 14:15 **MS17.03 - Surveillance & Second Primary Malignancies in Lung Cancer Survivors**  
Virginie Westeel, France
- 14:15 - 14:30 **MS17.04 - How Important Is Tobacco Cessation as Part of Lung Cancer Treatment?**  
Clarissa Baldotto, Brazil
- 14:30 - 15:00 **MS17.05 - Discussion**

MS18

**13:30 - 15:00** **Type: Mini Symposium**  
**Title: Management of SCLC Patients Not Represented in Clinical Trials**  
Track: Small Cell Lung Cancer/NET  
Moderation: Jie Wang, China; Everett Vokes, USA

- 13:30 - 13:50 **MS18.01 - Treatment of Patients with Poor Performance Status (ECOG 3-4)**  
Luiz Henrique De Lima Araujo, Brazil
- 13:50 - 14:10 **MS18.02 - Treatment of Elderly Patients with SCLC**  
Karen Kelly, USA
- 14:10 - 14:30 **MS18.03 - Treatment of SCLC transformed from EGFR Mutant Adenocarcinoma**  
Nicolas Marcoux, USA
- 14:30 - 14:50 **MS18.04 - Retreatment with Platinum and Etoposide and Treatment Beyond Second Line**  
Charles Butts, Canada
- 14:50 - 15:00 **MS18.05 - Q&A**

PC06

**13:30 - 15:00** **Type: Pro-Con Session**  
**Title: Controversies in Immunobiomarker Testing**  
Track: Pathology  
Moderation: Christian Couture, Canada; Erik Thunnissen, Netherlands

- 13:30 - 13:50 **PC06.01 - Laboratory Developed Test - PRO**  
Dara Aisner, USA
- 13:50 - 14:10 **PC06.02 - Laboratory Developed Test - CON**  
Mari Mino-Kenudson, USA
- 14:10 - 14:30 **PC06.03 - Tumor Mutation Burden - PRO**  
Lynette Sholl, USA
- 14:30 - 14:50 **PC06.04 - Tumor Mutation Burden - CON**  
Lukas Bubendorf, Switzerland
- 14:50 - 15:00 **PC06.05 - Q&A**



## PC07

|                      |  |
|----------------------|--|
| <b>13:30 - 15:00</b> | <b>Type: Pro-Con Session</b><br><b>Title: The Future of Cytotoxic Chemotherapy in Advanced NSCLC</b><br>Track: Advanced NSCLC<br>Moderation: Stephanie Brule, Canada; Terefumi Kato, Japan |
| 13:30 - 13:50        | <b>PC07.01 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - For</b><br>Suresh Ramalingam, USA  |
| 13:50 - 14:10        | <b>PC07.02 - Debate 1: Chemotherapy Will Become a Thing of the past in the Management of Advanced NSCLC - Against</b><br>Keunchil Park, Korea  |
| 14:10 - 14:30        | <b>PC07.03 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - IO alone</b><br>Leora Horn, USA   |
| 14:30 - 14:50        | <b>PC07.04 - Debate 2: For Wild-Type NSCLC, Which Will Be the Preferred Strategy: IO alone versus Chemo + IO - Chemo + IO</b><br>Federico Cappuzzo, Italy                                  |
| 14:50 - 15:00        | <b>PC07.05 - Q&amp;A</b>   |

## PC08

|                      |   |
|----------------------|---|
| <b>13:30 - 15:00</b> | <b>Type: Pro-Con Session</b><br><b>Title: The Great Oligometastatic Debates</b><br>Track: Oligometastatic NSCLC<br>Moderation: Stephen Harrow, UK; Melissa Johnson, USA |
| 13:30 - 13:40        | <b>PC08.01 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (PRO)</b><br>Howard (Jack) West, USA            |
| 13:40 - 13:50        | <b>PC08.02 - Debate #1: Locally Ablative Therapies Should Be Standard Treatment for Patients with NSCLC Oligometastases (CON)</b><br>Puneeth Iyengar, USA               |
| 13:50 - 14:00        | <b>PC08.03 - Discussion</b>   |
| 14:00 - 14:10        | <b>PC08.04 - Debate #2: Optimal Therapy for OM Disease: Thoracic Surgery Should Be the Treatment of Choice Whenever Possible</b><br>David Jones, USA                    |
| 14:10 - 14:20        | <b>PC08.05 - Debate #2: Keep Calm and Beam On: Thoracic Radiation Obviates the Need for Surgery</b><br>Matthias Guckenberger, Switzerland                               |
| 14:20 - 14:30        | <b>PC08.06 - Discussion</b>   |



- 14:30 - 14:40 **PC08.07 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (PRO)**  
Frances Shepherd, Canada
- 14:40 - 14:50 **PC08.08 - Debate #3: Brain Metastases with a Driver Mutation Should Be Treated with Systemic Therapy First (CON)**  
Marta Scorsetti, Italy
- 14:50 - 15:00 **PC08.09 - Discussion**

## ES03

**15:15 - 16:45** **Type: Educational Session**  
**Title: How to Manage Pleural Plaques and Pleural Effusion with Negative Pleural Biopsy**  
Track: Mesothelioma  
Moderation: Rolf Stahel, Switzerland; Marc De Perrot, Canada

- 15:15 - 15:30 **ES03.01 - Diagnosis of Mesothelioma Based on Cytology Alone**
- 15:30 - 15:45 **ES03.02 - Role of CT Scan to Follow Pleural Plaques**  
Demetris Patsios, Canada
- 15:45 - 16:00 **ES03.03 - When to Repeat Pleural Biopsies**  
Catherine Labbe, Canada
- 16:00 - 16:15 **ES03.04 - Role of Chemotherapy in Mesothelioma with Minimal Bulk Disease**  
Christopher Lee, Canada
- 16:15 - 16:30 **ES03.05 - Role of Surgery in T0 Mesothelioma**  
Seiki Hasegawa, Japan
- 16:30 - 16:45 **ES03.06 - Q&A**

## ES04

**15:15 - 16:45** **Type: Educational Session**  
**Title: Liquid Biopsies in Lung Cancer**  
Track: Targeted Therapy  
Moderation: Céline Mascaux, France; Geoffrey Oxnard, USA

- 15:15 - 15:35 **ES04.01 - Liquid Biopsies in Lung Cancer**  
Ming Tsao, Canada
- 15:35 - 15:55 **ES04.02 - Mechanisms of Resistance to Targeted Therapy**  
Christine Lovly, USA
- 15:55 - 16:15 **ES04.03 - Guiding Second Line Treatment in ALK + Patients (Sequence of Drugs, Rebiopsy?)**  
Enriqueta Felip, Spain





16:15 - 16:35 **ES04.04 - Overcoming Resistance by Improving Treatment Compliance**

Felipe Gomes, Brazil

16:35 - 16:45 **ES04.05 - Q&A**

#### ES05

15:15 - 16:45

**Type: Educational Session**

**Title: Collaboration Between Stakeholders to Improve Lung Cancer Research**

Track: Advocacy

Moderation: Bonnie Addario, USA; Toshiyuki Sawa, Japan

15:15 - 15:35

**ES05.01 - Linking the Stakeholders: Can Patient Groups, Clinical Researchers and the Pharmaceutical Industry Collaborate to Accelerate Research?**

Janet Freeman-Daily, USA

15:35 - 15:55

**ES05.02 - Can Patient Groups and Regulatory Bodies Work Together to Make Clinical Research Easier?**

Andrea Ferris, USA

15:55 - 16:15

**ES05.03 - Discrepancies and Sustainable Access to Innovative Therapies: Transforming Patient Experience in to Patient Voice**

Jesme Fox, UK

16:15 - 16:35

**ES05.04 - Challenges and Solutions in Engaging with the Health Technology Assessment Process in Canada**

Christina Sit, Canada

16:35 - 16:45

**ES05.05 - Q&A**

#### GR02

15:15 - 16:45

**Type: Grand Rounds**

**Title: Management of N2 NSCLC - A Case Based Discussion**

Track: Treatment of Locoregional Disease - NSCLC

Moderation: Tomasz Grodzki, Poland; Linda Coate, Ireland

15:15 - 15:25

**GR02.01 - Case 1: Single Zone N2 (No Pneumonectomy Necessary)**

Ania Wrona, Poland

15:25 - 15:35

**GR02.02 - Case 2: Multiple N2 Bulky Primary**

Megan Daly, USA

15:35 - 15:45

**GR02.03 - Case 3: Post Operative Management of Incidentally Found N2 Disease**

Masaya Yotsukura, Japan

15:45 - 16:45

**GR02.04 - Panel Discussion**

David Harpole, USA; Hiroshi Date, Japan; Alexander Sun, Canada; Joop De Langen, Netherlands; Mary Duffy, Australia; Kathy Albain, USA



## MS19

|                      |   |
|----------------------|---|
| <b>15:15 - 16:45</b> | <b>Type: Mini Symposium</b><br><b>Title: Pulmonary Dilemmas with Immunotherapy</b><br>Track: Interventional Diagnostics/Pulmonary<br>Moderation: Sita Andarini, Indonesia |
| 15:15 - 15:35        | <b>MS19.01 - Target Therapy/Immunotherapy: Treatment Beyond Toxicity or Progression</b><br>Desiree Hao, Canada  |
| 15:35 - 15:55        | <b>MS19.02 - What Are the Clinical Features of IO Progression/Pseudoprogression and Radiation Fibrosis vs Recurrence</b><br>Chong-Kin Liam, Malaysia                      |
| 15:55 - 16:15        | <b>MS19.03 - Diagnostic Approaches Suspected IO Progression/Pseudoprogression and What/When to Rebiopsy for TT Progression</b><br>Kasia Czarnecka, Canada                 |
| 16:15 - 16:45        | <b>MS19.04 - Q&amp;A</b>  |

## MS20

|                      |  |
|----------------------|--|
| <b>15:15 - 16:45</b> | <b>Type: Mini Symposium</b><br><b>Title: Innovative and Evolving Strategies in Diagnosis and Management of Stage I NSCLC</b><br>Track: Treatment of Early Stage/Localized Disease<br>Moderation: Bob Li, Australia |
| 15:15 - 15:30        | <b>MS20.01 - Robotic and Innovative Surgery</b><br>Wael Hanna, Canada  |
| 15:30 - 15:45        | <b>MS20.02 - The Future of Radiosurgery</b><br>Billy Loo, USA  |
| 15:45 - 16:00        | <b>MS20.03 - Immunotherapy and Surgery: Neoadjuvant or Adjuvant? Is It Safe?</b><br>Jamie Chaft, USA   |
| 16:00 - 16:15        | <b>MS20.04 - Prediction of Clinical Outcome in NSCLC Using Integrative Genomics: Implications for Adjuvant Chemotherapy</b><br>Phillippe Broet, France   |
| 16:15 - 16:30        | <b>MS20.05 - Beyond Surgery - Support of the Surgical Patient</b><br>Katherine Kuhns, USA  |
| 16:30 - 16:45        | <b>MS20.06 - Less Is More: Segmentectomy in the Management of Early Stage NSCLC</b><br>Shun-ichi Watanabe, Japan   |



## MS21

**15:15 - 16:45** Type: Mini Symposium  
Title: Giants in Thoracic Oncology  
Moderation: Ronald Feld, Canada

15:15 - 15:25 Surgery and its Evolution

15:25 - 15:35 Chemotherapy through the 21st Century  
David Johnson, USA

15:35 - 15:45 Revolution in Radiation

15:45 - 15:55 Targeted Therapy - The Second Revolution  
Frances Shepherd, Canada

15:55 - 16:05 Quality of Life - Are we Paying Enough Attention?  
Richard Gralla, USA

16:05 - 16:15 Immunotherapy - Sequence or Combination?  
Roy Herbst, USA

16:15 - 16:25 The Growing Role of Biomarkers in Treatment Selection  
Fred Hirsch, USA

16:25 - 16:35 Where will we be in 10 years?  
Paul Bunn, Jr., USA

16:35 - 16:45 Q&A

**16:45 - 18:00** Type: Poster Viewing  
Title: Poster Viewing Reception in the Exhibit Hall

**16:45 - 17:45** Type: IASLC Business Meeting  
Title: IASLC Business Meeting

## ISS13

**18:00 - 19:30** Type: Industry Supported Symposia  
Title: Symposium Supported by AstraZeneca

**20:00 - 23:30** Type: Networking Opportunity  
Title: Conference Dinner (Ticketed Event)



## Wednesday, September 26, 2018

### MTE20

**07:00 - 08:00** Type: Meet the Expert  
Title: Molecular Testing in Small Samples (Ticketed Session)  
Track: Pathology

**07:00 - 07:30** MTE20.01 - Molecular Testing in Small Samples  
John Longshore, USA

**07:30 - 08:00** MTE20.02 - Molecular Testing in Small Samples  
Jin-Haeng Chung, Korea

### MTE21

**07:00 - 08:00** Type: Meet the Expert  
Title: Can I Treat Brain Metastasis with Immunotherapy? (Ticketed Session)  
Track: Immunocology

**07:00 - 07:30** MTE21.01 - Can I Treat Brain Metastasis with Immunotherapy?  
Sarah Goldberg, USA

**07:30 - 08:00** MTE21.02 - Can I Treat Brain Metastasis with Immunotherapy?

### MTE22

**07:00 - 08:00** Type: Meet the Expert  
Title: Incorporation of Smoking Cessation in Clinical Care (Ticketed Session)  
Track: Prevention and Tobacco Control

**07:00 - 07:30** MTE22.01 - Integration of Cessation and Lung Cancer Screening  
Matthew Steliga, USA

**07:30 - 08:00** MTE22.02 - Cessation and Clinical Lung Cancer Care  
Jamie Ostroff, USA

### MTE23

**07:00 - 08:00** Type: Meet the Expert  
Title: Surgical Considerations Following Induction Therapy for Stage IIIA Disease (Ticketed Session)  
Track: Treatment of Locoregional Disease - NSCLC

**07:00 - 07:30** MTE23.01 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease  
Eric Vallieres, USA

**07:30 - 08:00** MTE23.02 - Surgical Considerations Following Induction Therapy for Stage IIIA Disease  
Jonathan Spicer, Canada



## MTE24

**07:00 - 08:00** Type: Meet the Expert  
 Title: Multiple Lung nodules; Resect, Radiate or Watch? (Ticketed Session)  
 Track: Treatment of Early Stage/Localized Disease

07:00 - 07:30 MTE24.01 - Surgery vs SABR for Early NSCLC  
 Thomas D'amico, USA

07:30 - 08:00 MTE24.02 - Identifying High Risk Lesions  
 David Ball, Australia

## MTE25

**07:00 - 08:00** Type: Meet the Expert  
 Title: Enhancing the Care of Your Older Adult Population with Lung Cancer (Ticketed Session)  
 Track: Nursing and Allied Professionals

07:00 - 08:00 MTE25.01 - Enhancing the Care of Your Older Adult Population with Lung Cancer  
 Martine Puts, Canada

## MTE26

**07:00 - 08:00** Type: Meet the Expert  
 Title: New Paradigms in Symptom Management in Lung Cancer (Ticketed Session)  
 Track: Treatment in the Real World - Support, Survivorship, Systems Research

07:00 - 07:30 MTE26.01 - Interventional Pulmonologist  
 Patricia Rivera, USA

07:30 - 08:00 MTE26.02 - RN/APN

## MTE27

**07:00 - 08:00** Type: Meet the Expert  
 Title: Controversies in Radiotherapy for SCLC (Ticketed Session)  
 Track: Small Cell Lung Cancer/NET

07:00 - 08:00 MTE27.01 - Radiotherapy in ES-SCLC  
 Elizabeth Gore, USA

## SH02

**07:00 - 08:00** Type: Scientific Highlights  
 Title: Highlight of the Previous Day Sessions



## MTE28

**07:00 - 08:00** Type: Meet the Expert  
 Title: Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP  
 (Ticketed Session)  
 Track: Interventional Diagnostics/Pulmonary

**07:00 - 08:00** MTE28.01 - Lessons from the Past-What I Would Not Do Again in Diagnostic and Therapeutic IP  
 Navneet Singh, India

## PL03

**08:15 - 09:45** Type: Plenary Session  
 Title: Call to Action - Challenges Ahead  
 Moderation: Gail Darling, Canada; Nagahiro Saijo, Japan

**08:15 - 08:30** PL03.01 - From Bench to Bedside

**08:30 - 08:45** PL03.02 - Host Immunity - No Longer a Passive Bystander  
 Julie Brahmer, USA

**08:45 - 09:00** PL03.03 - Beaming into the Future  
 David Palma, Canada

**09:00 - 09:15** PL03.04 - A Cut Above

**09:15 - 09:30** PL03.05 - It's All In The Tissue  
 Keith Kerr, UK

**09:30 - 09:40** PL03.06 - The Future of Targeted Therapy  
 Tetsuya Mitsudomi, Japan

**09:45 - 10:30** Type: Poster Viewing  
 Title: Poster Viewing - Exhibit Hall

## ES06

**10:30 - 12:00** Type: Educational Session  
 Title: Oligometastatic Disease  
 Track: Oligometastatic NSCLC  
 Moderation: Renato Martins, USA; Gaetano Rocco, Italy

**10:30 - 10:50** ES06.01 - Current Clinical Trials in Oligometastases  
 Anne-Marie Dingemans, Netherlands

**10:50 - 11:10** ES06.02 - Integrating New Systemic Therapy into Trials in OMD





Sanjay Popat, UK

- 11:10 - 11:30 **ES06.03 - Developments in SBRT in the Oligometastatic Paradigm in NSCLC**  
Patrick Cheung, Canada
- 11:30 - 11:50 **ES06.04 - Surgical Considerations in OMD**  
Jessica Donington, USA
- 11:50 - 12:00 **ES06.05 - Q&A**

## MS22

**10:30 - 12:00** **Type: Mini Symposium**  
**Title: Biology of the Lung and Lung Cancer**  
Track: Biology  
Moderation: Matthew Meyerson, USA; Geoffrey Liu, Canada

- 10:30 - 10:45 **MS22.01 - Lung Development and Stem Cells**  
Carla Kim, USA
- 10:45 - 11:00 **MS22.02 - Epigenetic Alterations in Lung Cancer Development**  
Wan Lam, Canada
- 11:00 - 11:15 **MS22.03 - Non-Coding RNA in Lung Cancer**  
Sven Diederichs, Germany
- 11:15 - 11:30 **MS22.04 - Genomics of Resistance and Response in Lung Cancer**
- 11:30 - 11:45 **MS22.05 - Inflammation in Lung Cancer**  
Katerina Politi, USA
- 11:45 - 12:00 **MS22.06 - Discussant**

## MS23

**10:30 - 12:00** **Type: Mini Symposium**  
**Title: What's New in Targeted Therapy?**  
Track: Targeted Therapy  
Moderation: Vera Hirsh, Canada; Alexander Drilon, USA

- 10:30 - 10:45 **MS23.01 - Novel Combinations of Targeted Therapies**  
Pasi Jänne, USA
- 10:45 - 11:00 **MS23.02 - Emerging or Rare Targets - Fusions, Mutational Burden Etc**



- 11:00 - 11:15 **MS23.03 - Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)**  
Marina Garassino, Italy
- 11:15 - 11:30 **MS23.04 - Targeting Driver Oncogenes in Stage 1-3 NSCLC**  
Helena Yu, USA
- 11:30 - 11:45 **MS23.05 - Role of Immunotherapy in Patients with Molecular Driven NSCLC**  
Benjamin Besse, France
- 11:45 - 12:00 **MS23.06 - Q&A**

## MS24

- 10:30 - 12:00** **Type: Mini Symposium**  
**Title: Global Perspectives on Tobacco Control**  
Track: Prevention and Tobacco Control  
Moderation: Rui, Haddad, Brazil; Desmond Carney, Ireland

- 10:30 - 10:45 **MS24.01 - Tobacco Control Impacting the Effectiveness and Cost of Cancer Care**  
Graham Warren, USA
- 10:45 - 11:00 **MS24.02 - Legal Action Against the Tobacco Industry in Europe**  
Wanda De Kanter, Netherlands
- 11:00 - 11:15 **MS24.03 - The Importance of Physician Involvement in Tobacco Control**  
Jacek Jassem, Poland
- 11:15 - 11:30 **MS24.04 - Challenges of Tobacco Control in China**  
Caicun Zhou, China
- 11:30 - 11:45 **MS24.05 - Money Matters: Portfolio Divestment as a Means of Tobacco Control**  
Bronwyn King, Australia
- 11:45 - 12:00 **MS24.06 - Q&A**

## MS25

- 10:30 - 12:00** **Type: Mini Symposium**  
**Title: Genetic and Prognostic Markers in Mesothelioma; Going Beyond the Histology Subtypes**  
Track: Mesothelioma  
Moderation: Dean Fennell, UK; Aaron Mansfield, USA

- 10:30 - 10:45 **MS25.01 - Impact of Tumor Volume on Outcome: What Are the Limitations?**  
Anna Nowak, Australia
- 10:45 - 11:00 **MS25.02 - How Should P16, BAP1, and NF2 Mutations Be Integrated in Therapeutic Algorithms?**  
Francoise Galateau-Salle, France



- 11:00 - 11:15      **MS25.03 - Impact of Innate and Adaptive Tumor Infiltrating Cells on Prognosis**  
Thomas John, Australia
- 11:15 - 11:30      **MS25.04 - Biomarkers in Clinical Practice: Is It Prime Time?**  
Harvey Pass, USA
- 11:30 - 11:45      **MS25.05 - Targeting the Micro-RNA: A New Therapeutic Venture**  
Nick Pavlakis, Australia
- 11:45 - 12:00      **MS25.06 - Q&A**

## MS26

- 10:30 - 12:00**      **Type: Mini Symposium**  
**Title: From Textbook to Practice Around the World**  
Track: Treatment in the Real World - Support, Survivorship, Systems Research  
Moderation: Jarushka Naidoo, USA; Fabio Moraes, Brazil

- 10:30 - 10:45      **MS26.01 - Translation of Clinical Data to Real World - Asia**  
Dae Ho Lee, Korea
- 10:45 - 11:00      **MS26.02 - Translation of Clinical Data to Real World - North America**  
Cheryl Ho, Canada
- 11:00 - 11:15      **MS26.03 - Translation of Clinical Data to Real World - Europe**  
Fabrice Barlesi, France
- 11:15 - 11:30      **MS26.04 - Translation of Clinical Data to Real World - Latin America/Africa**  
Gilberto De Lima Lopes, USA
- 11:30 - 12:00      **MS26.05 - Panel Discussion**

## MS27

- 10:30 - 12:00**      **Type: Mini Symposium**  
**Title: Therapeutic Implications of Staging Issues**  
Track: Treatment of Early Stage/Localized Disease  
Moderation: Janet Edwards, Canada; Masaoki Ito, Japan
- 10:30 - 10:45      **MS27.01 - Staging of Lymph Nodes in Early Stage NSCLC: Therapeutic Implications**  
Raymond Osarogiagbon, USA
- 10:45 - 11:00      **MS27.02 - Invasive Staging in Medically Inoperable Patients Treated with SBRT: Is It Necessary?**  
Anand Swaminath, Canada
- 11:00 - 11:15      **MS27.03 - Multiple Lung Nodules: M1, T4 or T3? Are They Really Different?**  
Frank Detterbeck, USA



- 11:15 - 11:30 **MS27.04 - Therapeutic Implications of AJCC 8th Edition T1 Subsets**  
Laura Donahoe, Canada
- 11:30 - 11:45 **MS27.05 - The Future of Precision Therapy for Localized Lung Cancer**  
Takashi Seto, Japan
- 11:45 - 12:00 **MS27.06 - Q&A**

## PC09

- 10:30 - 12:00**  
Type: Pro-Con Session  
Title: Approaches to Management of Advanced NSCLC  
Track: Advanced NSCLC  
Moderation: Gwyn Bebb, Canada; Kazuhiko Nakagawa, Japan
- 10:30 - 10:45 **PC09.01 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Early**  
Qing (Jolie) Zhou, China
- 10:45 - 11:00 **PC09.02 - Debate 1: Early vs Delayed Treatment of Asymptomatic Brain Metastases in Wild-Type NSCLC - Delayed**  
Walter Curran Jr., USA
- 11:00 - 11:15 **PC09.03 - Discussion**
- 11:15 - 11:30 **PC09.04 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - NSCLC**  
Noemi Reguart, Spain
- 11:30 - 11:45 **PC09.05 - Debate 2: Large Cell Neuroendocrine Carcinoma Should Be Treated like NSCLC or SCLC? - SCLC**  
Scott Laurie, Canada
- 11:45 - 12:00 **PC09.06 - Discussion**
- 12:00 - 13:30**  
Type: Poster Viewing  
Title: Poster Viewing - Exhibit Hall

## ISS14

- 12:00 - 13:30**  
Type: Industry Supported Symposia  
Title: Symposium Supported by AbbVie: New Frontiers in Lung Cancer



## ES07

|               |  |
|---------------|--|
| 13:30 - 15:00 | <b>Type: Educational Session</b><br><b>Title: Beyond the Diagnosis - Collaborative Care for Change</b><br>Track: Nursing and Allied Professionals<br>Moderation: Maria Guerin, UK; Diane Zawisza, Canada |
| 13:30 - 13:50 | <b>ES07.01 - A Moment in Time for the Unplanned Conversations</b><br>Kelly Mcguigan, Canada  |
| 13:50 - 14:00 | <b>ES07.02 - Special Needs and Wellness in Lung Cancer Patients - Australian Perspective</b><br>Maria Ftanou, Australia  |
| 14:00 - 14:10 | <b>ES07.03 - Special Needs and Wellness in Lung Cancer Patients - European Perspective</b><br>Rossie Navon, Israel   |
| 14:10 - 14:30 | <b>ES07.04 - Leveraging Social Media to Change the Public Conversation on Lung Cancer Stigma</b><br>Lisa Carter-Harris, USA  |
| 14:30 - 14:50 | <b>ES07.05 - Research Update: Patient's Perspective on Living with Malignant Pleural Mesothelioma</b><br>Angela Tod, UK  |
| 14:50 - 15:00 | <b>ES07.06 - Q&amp;A</b>   |

## ES08

|               |   |
|---------------|---|
| 13:30 - 15:00 | <b>Type: Educational Session</b><br><b>Title: The Pathologist - An Essential Member of the Patient Care Team</b><br>Track: Pathology<br>Moderation: Claudia Poleri, Argentina |
| 13:30 - 13:50 | <b>ES08.01 - Targeted Therapy</b><br>Yasushi Yatabe, Japan  |
| 13:50 - 14:10 | <b>ES08.02 - Immunotherapy</b><br>Sylvie Lantuejoul, France   |
| 14:10 - 14:30 | <b>ES08.03 - Mesothelioma, Thymic Epithelial Tumors and Others</b><br>Andrew Nicholson, UK  |
| 14:30 - 14:50 | <b>ES08.04 - Neoadjuvant Therapy</b><br>Ignacio Wistuba, USA  |
| 14:50 - 15:00 | <b>ES08.05 - Q&amp;A</b>  |



## MS28

|               |  |
|---------------|--|
| 13:30 - 15:00 | <b>Type: Mini Symposium</b><br><b>Title: IO Combinations in Advanced NSCLC</b><br>Track: Immunocology<br>Moderation: Corey Langer, USA |
| 13:30 - 13:45 | <b>MS28.01 - Understanding the Rationale for Combining IO Agents</b><br>Edward Garon, USA  |
| 13:45 - 14:00 | <b>MS28.02 - Combination IO+IO</b><br>Myung-ju Ahn, Korea  |
| 14:00 - 14:15 | <b>MS28.03 - Combinatorial IO + Chemo</b><br>Rosalyn Juergens, Canada  |
| 14:15 - 14:30 | <b>MS28.04 - Combination with Targeted Therapies</b><br>Ross Soo, Singapore  |
| 14:30 - 14:45 | <b>MS28.05 - Combining IO with Radiation</b><br>Corinne Faivre-Finn, UK  |
| 14:45 - 15:00 | <b>MS28.06 - Q&amp;A</b>   |

## MS29

|               |  |
|---------------|--|
| 13:30 - 15:00 | <b>Type: Mini Symposium</b><br><b>Title: Selection into Screening Programs: Interplay of Risk Algorithms, Genetic Markers and Biomarkers</b><br>Track: Screening and Early Detection<br>Moderation: John Goffin, Canada; Betty Tong, USA |
| 13:30 - 13:45 | <b>MS29.01 - Assessment of Risk Prediction Algorithms for Entry into Screening Programs</b><br>Martin Tammemagi, Canada  |
| 13:45 - 14:00 | <b>MS29.02 - Defining Screening Frequency &amp; Duration Using Risk Prediction Algorithms and CT Image Findings</b><br>Kevin Ten Haaf, Netherlands   |
| 14:00 - 14:15 | <b>MS29.03 - Polygenic Risk Score for Risk Assessment</b><br>Rayjean Hung, Canada  |
| 14:15 - 14:30 | <b>MS29.04 - LuCID Exhaled Breath Analysis</b><br>Marc Van Der Schee, UK   |
| 14:30 - 14:45 | <b>MS29.05 - Early Detection Biomarker Development: Is Success on the Horizon?</b><br>Peter Mazzone, USA   |
| 14:45 - 15:00 | <b>MS29.06 - Q&amp;A</b>   |





## MS30

|                      |   |
|----------------------|---|
| <b>13:30 - 15:00</b> | <b>Type: Mini Symposium</b><br><b>Title: Modern Day RT in LA NSCLC: Where Is the Evidence?</b><br>Track: Treatment of Locoregional Disease - NSCLC<br>Moderation: Fiona Hegi-Johnson, Australia; Yuko Nakayama, Japan |
| 13:30 - 13:45        | <b>MS30.01 - Overview of RT Technology in LA NSCLC (IMRT, VMAT, IGRT)</b><br>Gerard Hanna, Ireland  |
| 13:45 - 14:00        | <b>MS30.02 - What Evidence Is Available to Support RT Technology in LA NSCLC (including Protons)?</b><br>Yong Chan Ahn, Korea   |
| 14:00 - 14:15        | <b>MS30.03 - What Evidence Is Available to Support RT Treatment Intensification in LA NSCLC?</b><br>Jeffrey Bradley, USA  |
| 14:15 - 14:30        | <b>MS30.04 - Perspective</b><br>Maria Werner-Wasik, USA   |
| 14:30 - 14:45        | <b>MS30.05 - Nutritional Management During Radical Radiotherapy</b><br>Rhys White, UK   |
| 14:45 - 15:00        | <b>MS30.06 - Q&amp;A</b>  |

## MS31

|                      |  |
|----------------------|--|
| <b>13:30 - 15:00</b> | <b>Type: Mini Symposium</b><br><b>Title: Clinical Science in Mesothelioma</b><br>Track: Mesothelioma<br>Moderation: Daniel Sterman, USA; Haining Yang, USA |
| 13:30 - 13:45        | <b>MS31.01 - Mechanisms and Targets for BAP1 Activity</b><br>Michele Carbone, USA  |
| 13:45 - 14:00        | <b>MS31.02 - Clinical Implementation of BAP1 Inhibitors</b><br>Paul Baas, Netherlands  |
| 14:00 - 14:15        | <b>MS31.03 - Targeting the Hyppo Pathway</b><br>David Jablons, USA   |
| 14:15 - 14:30        | <b>MS31.04 - CAR-T and ADC's in MPM</b><br>Prasad Adusumilli, USA  |
| 14:30 - 14:45        | <b>MS31.05 - Vaccination and Antibody-Based Therapy in Mesothelioma</b><br>Joachim Aerts, Netherlands  |
| 14:45 - 15:00        | <b>MS31.06 - Q&amp;A</b>   |



## MS32

**13:30 - 15:00**      **Type: Mini Symposium**  
**Title: SCLC - From Benchside to Bedside - Clinical Science Session**  
 Track: Small Cell Lung Cancer/NET  
 Moderation: Alex Adjei, USA

13:30 - 13:45      **MS32.01 - Genetic Mouse Models (GEMMS)**  
 Trudy Oliver, USA

13:45 - 14:00      **MS32.02 - Patient Derived Models (PDX & CTC-Derived)**  
 Anna Farago, USA

14:00 - 14:15      **MS32.03 - Liquid Biopsies for Drug Development in SCLC**  
 Caroline Dive, UK

14:15 - 14:30      **MS32.04 - Molecular Phenotypes of SCLC**  
 Adi Gazdar, USA

14:30 - 14:45      **MS32.05 - Targeting DNA Damage and Repair**  
 Lauren Byers, USA

14:45 - 15:00      **MS32.06 - Epigenetic Targets**  
 John Poirier, USA

## PL04

**15:15 - 16:30**      **Type: Plenary Session**  
**Title: Take Action - Key Messages from WCLC 2018 and Goals for 2019**  
 Moderation: Natasha Leighl, Canada; Robert Pirker, Austria

15:15 - 15:20      **PL04.01 - Med Onco**  
 David R Gandara, USA

15:20 - 15:25      **PL04.02 - Pathology**  
 Fred Hirsch, USA

15:25 - 15:30      **PL04.03 - Surgery**  
 Ramon Rami-Porta, Spain

15:30 - 15:35      **PL04.04 - Americas**  
 Clarissa Mathias, Brazil

15:35 - 15:40      **PL04.05 - Asia Pacific**  
 Michael Boyer, Australia

15:40 - 15:45      **PL04.06 - Rad Onc**  
 Jose Belderbos, Netherlands

15:45 - 16:25      **PL04.07 - Discussion and Q&A**

16:25 - 16:30      **PL04.08 - Invitation to WCLC 2019 Barcelona, Spain**